Project

Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers

Automatically Closed · 2019 until 2020

Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Automatically Closed
Start Date
2019
End Date
2020
Financing
Industry
Study Design
Phase I
Labels
other tumors
Brief description/objective

Kombination von Nivolumab mit dem anti-IL8 monoklona-len Antikörper BMS-986253 in PatientInnen mit selektierten fortgeschrittenen soliden Malignomen und erhöhten IL-8 Blutspiegeln.